BioClin Therapeutics, Inc.

Release Summary

BioClin Therapeutics, a privately-held clinical stage drug development company, announced the closing of a $30 million Series B financing, led by new investors Sofinnova Ventures and Ysios Capital.

BioClin Therapeutics, Inc.